MX383206B - Preparación de anticuerpos de cultivos de célula de ovario de hámster chino para conjugación. - Google Patents

Preparación de anticuerpos de cultivos de célula de ovario de hámster chino para conjugación.

Info

Publication number
MX383206B
MX383206B MX2016006551A MX2016006551A MX383206B MX 383206 B MX383206 B MX 383206B MX 2016006551 A MX2016006551 A MX 2016006551A MX 2016006551 A MX2016006551 A MX 2016006551A MX 383206 B MX383206 B MX 383206B
Authority
MX
Mexico
Prior art keywords
antibody
oxidizing enzyme
conjugation
antibodies
preparation
Prior art date
Application number
MX2016006551A
Other languages
English (en)
Other versions
MX2016006551A (es
Inventor
Bradley Hayes
Damon Meyer
John Valliere-Douglass
Kevin Beam
Robert Lyon
Original Assignee
Seagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seagen Inc filed Critical Seagen Inc
Publication of MX2016006551A publication Critical patent/MX2016006551A/es
Publication of MX383206B publication Critical patent/MX383206B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/03—Oxidoreductases acting on sulfur groups as donors (1.8) with oxygen as acceptor (1.8.3)
    • C12Y108/03002—Thiol oxidase (1.8.3.2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una enzima oxidante de la célula CHO, particularmente QSOX1, puede sobrevivir un proceso de purificación de anticuerpo aparentemente rigurosos para reducir la eficiencia de la posterior conjugación del anticuerpo con un fármaco. Si la enzima oxidante sobrevive el procedimiento de purificación depende de cuáles técnicas de purificación se emplean que puede variar de un anticuerpo a otro. Sabiendo que la contaminación con una enzima oxidante de la célula CHO es un problema potencial para la posterior conjugación, un esquema de purificación adecuado puede visualizarse para cualquier anticuerpo que elimina o al menos reduce la(s) enzima(s) oxidante(s) a un nivel aceptable.
MX2016006551A 2013-11-25 2014-11-21 Preparación de anticuerpos de cultivos de célula de ovario de hámster chino para conjugación. MX383206B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361908568P 2013-11-25 2013-11-25
PCT/US2014/066889 WO2015077605A1 (en) 2013-11-25 2014-11-21 Preparing antibodies from cho cell cultures for conjugation

Publications (2)

Publication Number Publication Date
MX2016006551A MX2016006551A (es) 2016-09-06
MX383206B true MX383206B (es) 2025-03-13

Family

ID=53180202

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006551A MX383206B (es) 2013-11-25 2014-11-21 Preparación de anticuerpos de cultivos de célula de ovario de hámster chino para conjugación.

Country Status (14)

Country Link
US (2) US10457976B2 (es)
EP (1) EP3074036B1 (es)
JP (2) JP6529188B2 (es)
KR (1) KR102306493B1 (es)
CN (1) CN105979963B (es)
AU (1) AU2014352824B2 (es)
CA (1) CA2928238C (es)
DK (1) DK3074036T3 (es)
EA (1) EA034123B1 (es)
ES (1) ES2753269T3 (es)
IL (1) IL245190B (es)
MX (1) MX383206B (es)
SG (2) SG11201602995VA (es)
WO (1) WO2015077605A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150083689A (ko) * 2014-01-10 2015-07-20 삼성전자주식회사 항 c-Met 항체 정제 방법
WO2016121701A1 (ja) 2015-01-26 2016-08-04 株式会社カネカ 免疫グロブリンκ鎖可変領域含有タンパク質精製用アフィニティー分離マトリックス
CN108064286A (zh) 2015-01-26 2018-05-22 株式会社钟化 突变型免疫球蛋白κ链可变区结合性肽
ES2817751T3 (es) * 2015-12-21 2021-04-08 Pfizer Purificación de conjugados de anticuerpo-fármaco mediante el uso de un gradiente de fosfato de sodio
WO2017195638A1 (ja) * 2016-05-09 2017-11-16 株式会社カネカ 抗体またはκ鎖可変領域含有抗体断片の精製方法
WO2018116269A1 (en) * 2016-12-22 2018-06-28 Lupin Limited Depth filtration of a protein
EP3962924A1 (en) * 2019-05-03 2022-03-09 Genentech, Inc. Methods of reducing the enzymatic hydrolysis activity rate in a composition obtained from a purification platform
NZ784975A (en) 2019-08-06 2025-10-31 Glaxosmithkline Ip Dev Ltd Biopharmacuetical compositions and related methods
TW202323822A (zh) 2021-08-03 2023-06-16 英商葛蘭素史密斯克藍智慧財產發展有限公司 生藥組合物及穩定同位素標記肽之圖譜定位方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
ATE234635T1 (de) 1995-12-22 2003-04-15 Bristol Myers Squibb Co Verzweigte hydrazongruppen enthaltende kuppler
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
CN107213469A (zh) 2003-11-06 2017-09-29 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US8263750B2 (en) * 2006-03-16 2012-09-11 Amgen Inc. Method for purifying a protein using protein-A affinity chromatography using an intermediate wash step
BRPI0817182A2 (pt) * 2007-10-30 2015-03-17 Genentech Inc Método para purificar um anticorpo e composições
KR101238061B1 (ko) * 2009-03-31 2013-02-27 한화케미칼 주식회사 Ｖｃａｍ－１에 특이적으로 결합하는 인간 단일클론항체 및 그를 포함하는 염증성 질환 또는 암의 치료용 조성물
KR101772354B1 (ko) 2010-04-15 2017-08-28 시애틀 지네틱스, 인크. 표적화된 피롤로벤조디아제핀 접합체
CA2865486C (en) * 2012-03-07 2021-03-30 Yeda Research And Development Co. Ltd. Compositions for inhibition of quiescin sulfhydryl oxidase (qsox1) and uses of same
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer

Also Published As

Publication number Publication date
EP3074036A4 (en) 2017-07-26
IL245190B (en) 2021-02-28
ES2753269T3 (es) 2020-04-07
WO2015077605A1 (en) 2015-05-28
US20170159099A1 (en) 2017-06-08
CA2928238C (en) 2021-08-17
EP3074036B1 (en) 2019-09-18
EA034123B1 (ru) 2019-12-30
US10457976B2 (en) 2019-10-29
CN105979963A (zh) 2016-09-28
DK3074036T3 (da) 2019-11-18
KR102306493B1 (ko) 2021-09-28
CN105979963B (zh) 2020-03-03
EP3074036A1 (en) 2016-10-05
SG10201710475WA (en) 2018-01-30
JP2019048888A (ja) 2019-03-28
JP2016539130A (ja) 2016-12-15
SG11201602995VA (en) 2016-05-30
CA2928238A1 (en) 2015-05-28
AU2014352824B2 (en) 2019-07-18
US20200063180A1 (en) 2020-02-27
IL245190A0 (en) 2016-06-30
KR20160089454A (ko) 2016-07-27
MX2016006551A (es) 2016-09-06
EA201691094A1 (ru) 2016-09-30
AU2014352824A1 (en) 2016-05-12
JP6529188B2 (ja) 2019-06-12

Similar Documents

Publication Publication Date Title
MX383206B (es) Preparación de anticuerpos de cultivos de célula de ovario de hámster chino para conjugación.
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
EA202092987A3 (ru) Липид, содержащий докозапентаеновую кислоту
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
EA201790630A1 (ru) Способы получения рибозидов
CL2017000310A1 (es) Anticuerpos anti tigit
HUE057928T2 (hu) Coronaviridae családba tartozó vírus okozta fertõzések kezelésére szolgáló eljárások
UY32501A (es) Anticuerpo antagonista específico para el heterodímero alfa4-beta7
UY34824A (es) Nucleósidos de espirooxetano de uracilo
UY34342A (es) ?derivados de pirrolopirimidina y purina?.
PH12015501017A1 (en) Alternative uses for hbv assembly effectors
UY34401A (es) Métodos para el tratamiento de hcv
UY34402A (es) Métodos para el tratamiento de hcv
MX373660B (es) Fibroblastos de embrion de pollo inmortalizados.
BR112015022536A2 (pt) pilha soec com aquecedor integrado
UY34582A (es) Anticuerpos anti-cxcr3
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
CY1125447T1 (el) Ειδικες πρωτεινες για baff και b7rp1 και χρησεις αυτων
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
EA201600429A1 (ru) Способ очистки 2,5-дихлорфенола
UY34274A (es) Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv).
EA201790558A1 (ru) Композиция с пониженной иммуногенностью
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
TW201613981A (en) Compositions and methods for the diagnosis of rheumatoid arthritis
BR112016005972A2 (pt) plataforma semisubmersível equipada com um sistema de amplificação angular